



Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome

Yahiya Y. Syed¹

Published online: 10 July 2021
© Springer Nature 2021

Correction to: Drugs (2021) 81:587–594
<https://doi.org/10.1007/s40265-021-01481-6>

licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Page 3, Table 2, ‘Complete TMA response’ section:

“Serum creatinine $\geq 25\%$ \uparrow from BL^b (% pts) [95% CI]”

Should read:

“Serum creatinine $\geq 25\%$ improvement from BL^b (% pts) [95% CI]”

Page 3, Table 2, foot note ‘b’:

“^bComponent of complete TAM response”

Should read:

“^bComponent of complete TMA response”

The corrected Table 2 is as follows:

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons

The original article can be found online at <https://doi.org/10.1007/s40265-021-01481-6>.

✉ Yahiya Y. Syed
demail@springer.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

Table 2 Efficacy of ravulizumab in treatment-naïve patients with atypical haemolytic uremic syndrome in clinical studies

| Outcomes | Adults (<i>n</i> = 56) [19] | Paediatric pts (<i>n</i> = 18) [13, 21] |
|--|------------------------------|--|
| Complete TMA response ^a (% pts) [95% CI] | 53.6 [39.6–67.5] | 77.8 [52.4–93.6] |
| Platelet count $\geq 150 \times 10^9/L$ ^b (% pts) [95% CI] | 83.9 [73.4–94.4] | 94.4 [72.7–99.9] |
| Lactate dehydrogenase ≤ 246 U/L ^b (% pts) [95% CI] | 76.8 [64.8–88.7] | 88.9 [65.3–98.6] |
| Serum creatinine $\geq 25\%$ improvement from BL ^b (% pts) [95% CI] | 58.9 [45.2–72.7] | 83.3 [58.6–96.4] |
| Haematologic normalization ^c (% pts) [95% CI] | 73.2 [60.7–85.7] | 88.9 [NA] |
| Haemoglobin ≥ 20 g/L (% pts) [95% CI] | 71.4 [58.8–84.2] | 88.9 [65.3–98.6] |
| Median changes from BL at day 183 (BL) | | |
| Platelet count ($\times 10^9/L$) \uparrow | 125.0 (95.3) | 247.0 (51.3) |
| Lactate dehydrogenase (U/L) \downarrow | 310.8 (508) | 1851.5 (1963.0) |
| Estimated glomerular filtration rate (mL/min/1.73 m ²) \uparrow | 29.0 (10) | 80.0 (22.0) |
| Haemoglobin (g/L) \uparrow | 35.0 (85) | NA (74.3) |

BL baseline, NA not available, pts patients, TMA thrombotic microangiopathy, \uparrow increased, \downarrow decrease

^aPrimary endpoint, assessed through week 26; patients had to meet criteria for all TMA components concurrently, and each criterion had to be met at two separate assessments obtained ≥ 28 days apart and at any measurement in between

^bComponent of complete TMA response

^cPlatelet count $\geq 150 \times 10^9/L$ plus lactate dehydrogenase ≤ 246 U/L